
John Horowitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11521610/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 227-235.	1.4	6
2	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. American Heart Journal, 2022, 251, 13-24.	1.2	6
3	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care, 2021, 44, 1219-1227.	4.3	19
4	The N-AcetylCysteine and RAMipril in Takotsubo Syndrome Trial (NACRAM): Rationale and design of a randomised controlled trial of sequential N-Acetylcysteine and ramipril for the management of Takotsubo Syndrome. Contemporary Clinical Trials, 2020, 90, 105894.	0.8	14
5	Serial measurement of interleukinâ€6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‣Y trials. Journal of Thrombosis and Haemostasis, 2020, 18, 2287-2295.	1.9	14
6	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	5.5	207
7	Prediction of short―and longâ€ŧerm mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	2.9	20
8	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. Journal of Thrombosis and Thrombolysis, 2019, 47, 345-352.	1.0	13
9	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	1.2	224
10	Inorganic Nitrate in Angina Study: A Randomized Doubleâ€Blind Placebo ontrolled Trial. Journal of the American Heart Association, 2017, 6, .	1.6	11
11	Platelet Reactivity Is Independent of Left Atrial Wall Deformation in Patients with Atrial Fibrillation. Mediators of Inflammation, 2016, 2016, 1-5.	1.4	4
12	A randomized double-blind placebo-controlled crossover trial of sodium nitrate in patients with stable angina INAS. Future Cardiology, 2016, 12, 617-626.	0.5	4
13	The Authors Reply:. JACC: Cardiovascular Imaging, 2016, 9, 635-636.	2.3	Ο
14	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart, 2016, 102, 508-517.	1.2	67
15	Right Ventricular Involvement and Recovery After Acute Stress-Induced (Tako-tsubo) Cardiomyopathy. American Journal of Cardiology, 2016, 117, 775-780.	0.7	29
16	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. American Heart Journal, 2016, 175, 175-183.	1.2	16
17	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. Clinical Chemistry, 2015, 61, 368-378.	1.5	37
18	Improvement in Cardiac Energetics by Perhexiline in Heart Failure Due to DilatedÂCardiomyopathy. JACC: Heart Failure, 2015, 3, 202-211.	1.9	77

JOHN HOROWITZ

#	Article	IF	CITATIONS
19	Tako-Tsubo Cardiomyopathy: A Heart Stressed Out of Energy?. JACC: Cardiovascular Imaging, 2015, 8, 985-987.	2.3	57
20	Cardiac Energetic Impairment in Heart Disease and the Potential Role of Metabolic Modulators. Circulation: Cardiovascular Genetics, 2014, 7, 720-728.	5.1	18
21	Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics. Seminars in Thrombosis and Hemostasis, 2014, 40, 660-668.	1.5	13
22	Response to Letter Regarding Article, "Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation― Circulation, 2014, 129, e21-2.	1.6	1
23	Meta-Analysis of Clinical Correlates of Acute Mortality in Takotsubo Cardiomyopathy. American Journal of Cardiology, 2014, 113, 1420-1428.	0.7	175
24	High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation. Circulation, 2014, 129, 625-634.	1.6	110
25	Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). European Heart Journal, 2014, 35, 1255-1262.	1.0	121
26	Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy. International Journal of Cardiology, 2014, 174, 696-701.	0.8	207
27	Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. American Heart Journal, 2014, 168, 303-309.	1.2	128
28	N-Terminal Pro–B-Type Natriuretic Peptide for RiskÂAssessment in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2274-2284.	1.2	191
29	Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI. Heart, 2012, 98, 1278-1284.	1.2	100
30	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet, The, 2012, 380, 1749-1758.	6.3	175
31	Clinical Trials Update Esc Congress 2011. Cardiovascular Drugs and Therapy, 2012, 26, 77-84.	1.3	2
32	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537
33	Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction. International Journal of Cardiology, 2010, 139, 107-112.	0.8	11
34	Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal, 2010, 159, 331-339.	1.2	407
35	Metabolic Modulation With Perhexiline in Chronic Heart Failure. Circulation, 2005, 112, 3280-3288.	1.6	322